VNRX Key Statistics, Chart & Performance
The current stock price of VNRX is 0.2801 USD. In the past month the price decreased by -7.64%. In the past year, price decreased by -57.55%.
VNRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 20.3 | 16.67B | ||
| SOLV | SOLVENTUM CORP | 14.14 | 14.56B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.2 | 11.94B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 24.49 | 5.40B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.64 | 4.60B | ||
| HAE | HAEMONETICS CORP/MASS | 17.33 | 3.89B | ||
| ICUI | ICU MEDICAL INC | 18.9 | 3.71B | ||
| XRAY | DENTSPLY SIRONA INC | 7.83 | 2.47B | ||
| UFPT | UFP TECHNOLOGIES INC | 28.76 | 1.91B | ||
| NEOG | NEOGEN CORP | 24.42 | 1.59B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.10B | ||
| EMBC | EMBECTA CORP | 4.23 | 734.89M |
Related stock screener links
About VNRX
Company Profile
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 85 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Company Info
VOLITIONRX LTD
1489 West Warm Springs Road, Suite 110
Henderson NEVADA 78738 US
CEO: Cameron Reynolds
Employees: 85
Phone: 17024251561
VOLITIONRX LTD / VNRX FAQ
What does VOLITIONRX LTD do?
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 85 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
What is the stock price of VOLITIONRX LTD today?
The current stock price of VNRX is 0.2801 USD. The price increased by 0.04% in the last trading session.
What is the dividend status of VOLITIONRX LTD?
VNRX does not pay a dividend.
What is the ChartMill rating of VOLITIONRX LTD stock?
VNRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does VOLITIONRX LTD belong to?
VOLITIONRX LTD (VNRX) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
What is the Price/Earnings (PE) ratio of VOLITIONRX LTD (VNRX)?
VOLITIONRX LTD (VNRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.23).
What is the Short Interest ratio of VOLITIONRX LTD (VNRX) stock?
The outstanding short interest for VOLITIONRX LTD (VNRX) is 0.53% of its float.
VNRX Technical Analysis
VNRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VNRX. VNRX may be in some trouble as it scores bad on both profitability and health.
VNRX Financial Highlights
Over the last trailing twelve months VNRX reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 36.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -267.93% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VNRX Forecast & Estimates
11 analysts have analysed VNRX and the average price target is 2.21 USD. This implies a price increase of 689.01% is expected in the next year compared to the current price of 0.2801.
For the next year, analysts expect an EPS growth of 29.81% and a revenue growth 5.02% for VNRX